Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.
BIO Investor Forum Company Snapshot: InvivoSciences What is your company’s lead product or technology? InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D tissue models recapitulate the physiological properties…
Read more
NIH has partnered with the Biotechnology Industry Organization (BIO) to provide selected SBIR grantees premier visibility at the BIO International Convention. InvivoSciences (IVS) is one of the selected NIH Innovation Zone companies interacting with potential investors and business partners. BIO International Convention is the world’s largest conference attracting 15,000 biotech leaders from 65 countries. This…
Read more
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated…
Read more
InvivoSciences is a local Biotechnology company that develops and commercializes technologies to mass-manufacture human tissue models for drug screening and personalized/regenerative medicine, providing customers rapid, cost-effective solutions/services to discover new therapies. This summer two Edgewood students Lauren Netzel (Edgewood High School Senior) and Audrey Netzel (Edgewood High School Graduate, class of 2012) worked with InvivoSciences…
Read more
Torrey Pines Institute for Molecular Studies (TPIMS), a non-profit research institution and leader in advanced methods of drug discovery, and InvivoSciences Inc., an innovative company providing screening for first-in-class drug discovery, announced today a new collaboration to accelerate drug discovery in cardiac disease. Under the terms of the agreement, Torrey Pines Institute will work with InvivoSciences to screen the…
Read more
As a leading provider of 3D, ready-to-use human engineered tissues, Madison-based InvivoSciences has products and capabilities that are of interest to a global audience. Reaching that audience is one of the many reasons Wisconsin biotechnology leaders and company representatives made their way to Boston in June for the 20th annual BIO International Convention. Their presence was…
Read more
The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure. According to the Centers for Disease Control, about…
Read more
InvivoSciences, a Madison biotech, is teaming with Myomics, of Providence, R.I., to provide screening services using their combined resources. InvivoSciences provides engineered human heart tissues for companies working on drugs to treat heart disease while Myomics offers engineered muscle tissues to drug companies focused on fighting muscular dystrophy. Both companies also have developed robotic systems…
Read more
Wisconsin Company, InvivoSciences LLC (IVS), is honored to be chosen as a finalist alongside 3M and CardioDX in the highly competitive Medical Science-Analytic Systems category by Edison Awards. Other finalist include Abbott, Johnson and Johnson, Apple, The Dow Chemical, GE Health Care, The Proctor and Gamble Company. Winning an Edison Award has become one of…
Read more
Recent Comments